18F-FDG PET/CT Staging of Head and Neck Cancer: Interobserver Agreement and Accuracy-Results from Multicenter ACRIN 6685 Clinical Trial

J Nucl Med. 2022 Dec;63(12):1887-1890. doi: 10.2967/jnumed.122.263902. Epub 2022 May 12.

Abstract

To our knowledge, no prior multicenter clinical trial has reported interobserver agreement of 18F-FDG PET/CT scans for staging of clinical N0 neck in head and neck cancer. Methods: A total of 287 participants were recruited. For visual analysis, positive nodal uptake of 18F-FDG was defined as uptake visually greater than activity seen in the blood pool. Results: The negative predictive value of the 18F-FDG PET/CT for N0 clinical neck was 86% or above for visual assessment (95% CI, 86%-88%) for the 2 central readers and above 90% (95% CI, 90%-95%) for SUVmax for central reads and site reads dichotomized at the optimal cutoff value of 1.8 and the prespecified cutoff value of 3.5, respectively. The κ coefficients between the 2 expert readers and between central reads and site reads varied between 0.53 and 0.78. Conclusion: The NPV of the 18F-FDG PET/CT for N0 clinical neck was 86% or above for visual assessment and above 90% for SUVmax cut points of 1.8 and 3.5 with moderate to substantial agreements.

Keywords: FDG PET/CT; head and neck cancer; oncology: head and neck; staging.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Research Support, N.I.H., Extramural

MeSH terms

  • Fluorodeoxyglucose F18*
  • Head and Neck Neoplasms* / diagnostic imaging
  • Humans
  • Neoplasm Staging
  • Observer Variation
  • Positron Emission Tomography Computed Tomography
  • Radiopharmaceuticals
  • Tomography, X-Ray Computed / methods

Substances

  • Fluorodeoxyglucose F18
  • Radiopharmaceuticals